New! Sign up for our free email newsletter.
Science News
from research organizations

Combination therapy treats leishmaniasis, HIV patients

Date:
January 17, 2019
Source:
PLOS
Summary:
Coinfection with visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) has been observed in at least 35 countries on four continents and requires special case management. Currently, the World Health Organization recommends AmBisome monotherapy for treatment. Now, researchers have showed that a combination therapy of AmBisome and miltefosine is more effective.
Share:
FULL STORY

Coinfection with visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) has been observed in at least 35 countries on four continents and requires special case management. Currently, the World Health Organization recommends AmBisome monotherapy for treatment. Now, researchers reporting in PLOS Neglected Tropical Diseases have showed that a combination therapy of AmBisome and miltefosine is more effective.

HIV affects VL by increasing its incidence, altering its symptoms and severity, and worsening treatment outcomes and relapse rates. While affective antiretroviral therapies have lowered the incidence of VL in HIV, it still remains a prevalent co-infection in some places. In Northwest Ethiopia, HIV rates among VL patients range from 20 to 40%. Studies have shown that 30 mg/kg AmBisome is effective in 43-70% of HIV co-infected patients, and also carries toxicity and an increased risk of death.

In the new work, Séverine Blesson, of the Drugs for Neglected Diseases Initiative in Switzerland, and colleagues began a compassionate use clinical trial regimen combining AmBiosome and miltefosine in a treatment center in Northwest Ethiopia. Efficacy was measured by measuring parasite clearance at 29 days and 58 days. Out of 536 VL patients, 81 were HIV positive and 59 were enrolled in the trial. 19 of those received the standard of care, with AmBiosome monotherapy, and 39 received the combination therapy.

After 29 days, the adjusted efficacy was 50% for AmBisome along and 67% for the combination therapy. At day 58, is was 55% for the monotherapy and 88% for the combination. Additionally, no safety concerns about the combination therapy were identified.

"The results of this randomized trial strongly support a change in the treatment recommendations for HIV-VL co-infected patients," the researchers say. But, they also caution, "these results, even if encouraging, cannot be extrapolated to other settings without reservation."


Story Source:

Materials provided by PLOS. Note: Content may be edited for style and length.


Journal Reference:

  1. Ermias Diro, Severine Blesson, Tansy Edwards, Koert Ritmeijer, Helina Fikre, Henok Admassu, Aderajew Kibret, Sally J. Ellis, Clelia Bardonneau, Eduard E. Zijlstra, Peninah Soipei, Brian Mutinda, Raymond Omollo, Robert Kimutai, Gabriel Omwalo, Monique Wasunna, Fentahun Tadesse, Fabiana Alves, Nathalie Strub-Wourgaft, Asrat Hailu, Neal Alexander, Jorge Alvar. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLOS Neglected Tropical Diseases, 2019; 13 (1): e0006988 DOI: 10.1371/journal.pntd.0006988

Cite This Page:

PLOS. "Combination therapy treats leishmaniasis, HIV patients." ScienceDaily. ScienceDaily, 17 January 2019. <www.sciencedaily.com/releases/2019/01/190117142216.htm>.
PLOS. (2019, January 17). Combination therapy treats leishmaniasis, HIV patients. ScienceDaily. Retrieved July 17, 2024 from www.sciencedaily.com/releases/2019/01/190117142216.htm
PLOS. "Combination therapy treats leishmaniasis, HIV patients." ScienceDaily. www.sciencedaily.com/releases/2019/01/190117142216.htm (accessed July 17, 2024).

Explore More

from ScienceDaily

RELATED STORIES